Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125:861–70. https://doi.org/10.1093/brain/awf080.
Article
PubMed
Google Scholar
Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord. 2009;24:500–8. https://doi.org/10.1002/mds.22108.
Article
PubMed
Google Scholar
Adler CH, Beach TG, Hentz JG, Shill HA, Caviness JN, Driver-Dunckley E, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology. 2014;83:406–12. https://doi.org/10.1212/WNL.0000000000000641.
Article
PubMed
PubMed Central
Google Scholar
Jellinger KA, Logroscino G, Rizzo G, Copetti M, Arcuti S, Martino D, et al. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology. 2016;87:237–8. https://doi.org/10.1212/WNL.0000000000002876.
Article
PubMed
Google Scholar
Scherfler C, Schwarz J, Antonini A, Grosset D, Valldeoriola F, Marek K, et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord. 2007;22:1229–38. https://doi.org/10.1002/mds.21505.
Article
PubMed
Google Scholar
Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54:93–101. https://doi.org/10.1002/ana.10609.
Article
CAS
PubMed
Google Scholar
Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287:1653–61. https://doi.org/10.1001/jama.287.13.1653.
Article
Google Scholar
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:2498–508. https://doi.org/10.1056/NEJMoa033447.
Article
CAS
PubMed
Google Scholar
Marek KL, Seibyl J. Beta-CIT scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA-CIT and CALM-CIT study: long-term imaging assessment. Neurology. 2003;60:A293.
Google Scholar
Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, et al. Longitudinal follow-up of SWEDD subjects in the PRECEPT study. Neurology. 2014;82:1791–7. https://doi.org/10.1212/WNL.0000000000000424.
Article
PubMed
PubMed Central
Google Scholar
Dodel RC, Höffken H, Möller JC, Bornschein B, Klockgether T, Behr T, et al. Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach. Mov Disord. 2003;18(Suppl 7):S52–62. https://doi.org/10.1002/mds.10580.
Article
PubMed
Google Scholar
Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 1996;46:231–7. https://doi.org/10.1212/wnl.46.1.231.
Article
CAS
PubMed
Google Scholar
Ribeiro MJ, Vidailhet M, Loc'h C, Dupel C, Nguyen JP, Ponchant M, et al. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol. 2002;59:580–6. https://doi.org/10.1001/archneur.59.4.580.
Article
PubMed
Google Scholar
Ichise M, Kim YJ, Ballinger JR, Vines D, Erami SS, Tanaka F, et al. SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD. Neurology. 1999;52:1206–14. https://doi.org/10.1212/wnl.52.6.1206.
Article
CAS
PubMed
Google Scholar
Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol. 1995;38:589–98. https://doi.org/10.1002/ana.410380407.
Article
CAS
PubMed
Google Scholar
Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson’s disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord. 2000;15:692–8. https://doi.org/10.1002/1531-8257(200007)15:4<692::aid-mds1014>3.0.co;2-v.
Suwijn SR, van Boheemen CJ, de Haan RJ, Tissingh G, Booij J, de Bie RM. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review. EJNMMI Res. 2015;5:12. https://doi.org/10.1186/s13550-015-0087-1.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol. 2007;7:27. https://doi.org/10.1186/1471-2377-7-27.
Article
PubMed
PubMed Central
Google Scholar
Bajaj NP, Gontu V, Birchall J, Patterson J, Grosset DG, Lees AJ. Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study. J Neurol Neurosurg Psychiatry. 2010;81:1223–8. https://doi.org/10.1136/jnnp.2009.193391.
Article
PubMed
Google Scholar
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–4. https://doi.org/10.1136/jnnp.55.3.181.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988;51:745–52. https://doi.org/10.1136/jnnp.51.6.745.
Article
CAS
PubMed
PubMed Central
Google Scholar
Erro R, Schneider SA, Stamelou M, Quinn NP, Bhatia KP. What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies. J Neurol Neurosurg Psychiatry. 2016;87:319–23. https://doi.org/10.1136/jnnp-2014-310256.
Article
PubMed
Google Scholar
Conrado DJ, Nicholas T, Tsai K, Macha S, Sinha V, Stone J, et al. Dopamine transporter neuroimaging as an enrichment biomarker in early Parkinson's disease clinical trials: a disease progression modeling analysis. Clin Transl Sci. 2018;11:63–70. https://doi.org/10.1111/cts.12492.
Article
PubMed
Google Scholar
Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311:1670–83. https://doi.org/10.1001/jama.2014.3654.
Article
CAS
PubMed
Google Scholar
Stephenson D, Hill D, Cedarbaum JM, Tome M, Vamvakas S, Romero K, et al. The qualification of an enrichment biomarker for clinical trials targeting early stages of Parkinson's disease. J Parkinsons Dis. 2019;9:553–63. https://doi.org/10.3233/JPD-191648.
Article
CAS
PubMed
PubMed Central
Google Scholar
Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology. 2007;69:1480–90. https://doi.org/10.1212/01.wnl.0000277648.63931.c0.
Article
CAS
Google Scholar
Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, et al. The Parkinson’s progression markers initiative (PPMI) - establishing a PD biomarker cohort. Ann Clin Transl Neurol. 2018;5:1460–77. https://doi.org/10.1002/acn3.644.
Article
CAS
PubMed
PubMed Central
Google Scholar
European Medicines Agency. DaTSCAN: ioflupane (123l) [prescribing information]. 2000. https://www.ema.europa.eu/en/medicines/human/EPAR/datscan. Accessed 20 Sep 2020.
Google Scholar
US Food and Drug Administration. DaTscan (ioflupane I 123 injection) [prescribing information]. 2011. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022454sOrig1s000Lbl.pdf. Accessed 20 Sep 2020.
Google Scholar
European Medicines Agency. Qualification opinion on dopamine transporter imaging as an enrichment biomarker for Parkinson’s disease clinical trials in patients with early parkinsonian symptoms. 2018. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-dopamine-transporter-imaging-enrichment-biomarker-parkinsons-disease-clinical_en.pdf. Accessed 1 Sep 2020.
Google Scholar
de la Fuente-Fernández R. Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology. 2012;78:696–701. https://doi.org/10.1212/WNL.0b013e318248e520.
Article
PubMed
Google Scholar
de la Fuente-Fernández R, Lövblad KO. DaTscan and Parkinson's disease: DAT binding should not lead to binding decisions in clinical practice. Eur J Neurol. 2014;21:1351–2. https://doi.org/10.1111/ene.12458.
Article
PubMed
Google Scholar
Nicastro N, Burkhard PR, Garibotto V. Scan without evidence of dopaminergic deficit (SWEDD) in degenerative parkinsonism and dementia with Lewy bodies: a prospective study. J Neurol Sci. 2018;385:17–21. https://doi.org/10.1016/j.jns.2017.11.039.
Article
PubMed
Google Scholar
Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007;78:1176–81. https://doi.org/10.1136/jnnp.2006.110122.
Article
PubMed
PubMed Central
Google Scholar
Perju-Dumbrava LD, Kovacs GG, Pirker S, Jellinger K, Hoffmann M, Asenbaum S, et al. Dopamine transporter imaging in autopsy-confirmed Parkinson's disease and multiple system atrophy. Mov Disord. 2012;27:65–71. https://doi.org/10.1002/mds.24000.
Article
PubMed
Google Scholar
Ba F, Martin WRW. Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice. Parkinsonism Relat Disord. 2015;21:87–94. https://doi.org/10.1016/j.parkreldis.2014.11.007.
Article
PubMed
Google Scholar
Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, Smith BA, et al. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models. Neurobiol Dis. 2019;124:276–88. https://doi.org/10.1016/j.nbd.2018.10.016.
Article
CAS
PubMed
Google Scholar
Nicastro N, Garibotto V, Badoud S, Burkhard PR. Scan without evidence of dopaminergic deficit: a 10-year retrospective study. Parkinsonism Relat Disord. 2016;31:53–8. https://doi.org/10.1016/j.parkreldis.2016.07.002.
Article
PubMed
Google Scholar
Nicastro N, Garibotto V, Poncet A, Badoud S, Burkhard PR. Establishing on-site reference values for (123)I-FP-CIT SPECT (DaTSCAN(R)) using a cohort of individuals with non-degenerative conditions. Mol Imaging Biol. 2016;18:302–12. https://doi.org/10.1007/s11307-015-0889-6.
Article
CAS
PubMed
Google Scholar
Nicastro N, Garibotto V, Allali G, Assal F, Burkhard PR. Added value of combined semi-quantitative and visual [123I]FP-CIT SPECT analyses for the diagnosis of dementia with Lewy bodies. Clin Nucl Med. 2017;42:e96–e102. https://doi.org/10.1097/RLU.0000000000001477.
Article
PubMed
Google Scholar
Chang L-T. A method for attenuation correction in radionuclide computed tomography. IEEE Trans NuclSci. 1978;25:638–43. https://doi.org/10.1109/tns.1978.4329385.
Article
Google Scholar
Nobili F, Naseri M, De Carli F, Asenbaum S, Booij J, Darcourt J, et al. Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging. 2013;40:565–73. https://doi.org/10.1007/s00259-012-2304-8.
Article
PubMed
Google Scholar
Nichols KJ, Chen B, Tomas MB, Palestro CJ. Interpreting 123I-ioflupane dopamine transporter scans using hybrid scores. Eur J Hybrid Imaging. 2018;2:10. https://doi.org/10.1186/s41824-018-0028-0.
Article
PubMed
Google Scholar
Benamer HT, Oertel WH, Patterson J, Hadley DM, Pogarell O, Höffken H, et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov Disord. 2003;18:977–84. https://doi.org/10.1002/mds.10482.
Article
PubMed
Google Scholar
Marek K, Jennings D, Tabamo R, Seibyl J. INSPECT: an investigation of the effects of short-term treatment with pramipexole or levodopa on [123I]b-CIT and SPECT imaging in early Parkinson’s disease. Neurology. 2006;66:A112.
Article
Google Scholar
Sevigny J, Suhy J, Chiao P, Chen T, Klein G, Purcell D, et al. Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial. Alzheimer Dis Assoc Disord. 2016;30:1–7. https://doi.org/10.1097/WAD.0000000000000144.
Article
CAS
PubMed
Google Scholar